At present Alzheimer’s can only be confirmed by a postmortem. A definitive diagnostic test may lead to earlier detection of the disease and enable better medical intervention as well as helping distinguish Alzheimer’s from other forms of age-related dementia.
A diagnostic test could also greatly aid R&D of new pharmaceuticals to treat the disease.
The research program will apply Nanosphere’s proprietary Biobarcode technology for ultra-sensitive protein detection to Applied NeuroSolutions’ proprietary biomarkers, which have been shown to be 85% to 95% accurate in the detection of Alzheimer’s disease. Ultra-sensitive detection of these markers has the potential to lead to the next generation of diagnostic tests for Alzheimer’s disease.
“Applied NeuroSolutions has achieved significant progress with the development of its cerebrospinal fluid (CSF) test to detect p-tau, a biomarker for Alzheimer’s disease,” said William Moffitt, president and CEO of Nanosphere. “Using our proprietary technology could lead to the development of a more sensitive and specific test for future clinical use.”